Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7450461, 10 pages
http://dx.doi.org/10.1155/2016/7450461
Research Article

MicroRNA Profiling in Patients with Upper Tract Urothelial Carcinoma Associated with Balkan Endemic Nephropathy

1Research Centre for Genetic Engineering and Biotechnology “Georgi D. Efremov”, Macedonian Academy of Sciences and Arts, 1000 Skopje, Macedonia
2Institute of Pathology, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
3Clinic of Nephrology, Medical Faculty, University of Nis, 18000 Nis, Serbia
4Department of Clinical Research, Faculty of Medicine, University of Nis, 18000 Nis, Serbia
5Department of Medical Genetics, Medical University of Sofia, 1431 Sofia, Bulgaria

Received 25 December 2015; Revised 2 March 2016; Accepted 4 April 2016

Academic Editor: Charles H. Lawrie

Copyright © 2016 Katerina Popovska-Jankovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Polenakovic and V. Stefanovic, “Balkan nephropathy,” in Oxford Textbook of Clinical Nephrology, J. S. Cameron, A. M. Davison, J. P. Grunfeld, D. Kerr, and E. Ritz, Eds., pp. 857–866, Oxford University Press, Oxford, UK, 1st edition, 1992. View at Google Scholar
  2. L. Djukanović and Z. Radovanović, “Balkan endemic nephropathy,” in Clinical Nephrotoxins, M. E. De Broe, G. A. Porter, W. M. Bennett, and G. A. Verpooten, Eds., pp. 587–601, Kluwer Academic Publishers, Dordrecht, The Netherlands, 2003. View at Google Scholar
  3. V. Stefanovic and Z. Radovanovic, “Balkan endemic nephropathy and associated urothelial cancer,” Nature Clinical Practice Urology, vol. 5, no. 2, pp. 105–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Stefanovic, “Current status and research beyond year 2010 in Balkan endemic nephropathy,” BANTAO Journal, vol. 7, no. 2, pp. 4–9, 2009. View at Google Scholar
  5. V. Stefanovic, M. Polenakovic, and D. Toncheva, “Urothelial carcinoma associated with Balkan endemic nephropathy. A worldwide disease,” Pathologie Biologie, vol. 59, no. 5, pp. 286–291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Polenakovic and V. Stefanović, “What do we know about the Balkan endemic nephropathy and the uroepithelial tumors?” Prilozi, vol. 35, no. 1, pp. 11–15, 2014. View at Google Scholar
  7. L. J. Velickovic, T. Hattori, and V. Stefanovic, “Molecular markers in upper urothelial carcinoma associated to Balkan endemic nephropathy. Aristolochic acid as the major risk factor of the worldwide disease,” TheScientificWorldJournal, vol. 9, pp. 1360–1373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Toncheva, T. Dimitrov, and S. Stojanova, “Etiology of Balkan endemic nephropathy: a multifactorial disease?” European Journal of Epidemiology, vol. 14, no. 4, pp. 389–394, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ivic, “The problem of etiology of endemic nephropathy,” Lijecnicki Vjesnik, vol. 91, pp. 1278–1281, 1969. View at Google Scholar
  10. M. E. De Broe, “Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy,” Kidney International, vol. 81, no. 6, pp. 513–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-L. Vanherweghem, M. Depierreux, C. Tielemans et al., “Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs,” The Lancet, vol. 341, no. 8842, pp. 387–391, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. J. L. Nortier, M.-C. M. Martinez, H. H. Schmeiser et al., “Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi),” The New England Journal of Medicine, vol. 342, no. 23, pp. 1686–1692, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Vanhaelen, R. Vanhaelen-Fastre, P. But, and J.-L. Vanherweghem, “Identification of aristolochic acid in Chinese herbs,” The Lancet, vol. 343, no. 8890, p. 174, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-S. Yang, C.-H. Lin, S.-H. Chang, and H.-C. Hsu, “Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs,” American Journal of Kidney Diseases, vol. 35, no. 2, pp. 313–318, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. C.-H. Chang, Y.-M. Wang, A.-H. Yang, and S.-S. Chiang, “Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications,” American Journal of Nephrology, vol. 21, no. 6, pp. 441–448, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. G. M. Lord, T. Cook, V. M. Arlt, H. H. Schmeiser, G. Williams, and C. D. Pusey, “Urothelial malignant disease and Chinese herbal nephropathy,” The Lancet, vol. 358, no. 9292, pp. 1515–1516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. X.-B. Li, N.-Z. Xing, Y. Wang, X.-P. Hu, H. Yin, and X.-D. Zhang, “Transitional cell carcinoma in renal transplant recipients: a single center experience,” International Journal of Urology, vol. 15, no. 1, pp. 53–57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Simmons, “Epigenetic influence and disease,” Nature Education, vol. 1, no. 1, article 6, 2008. View at Google Scholar
  19. R. Staneva, B. Rukova, S. Hadjidekova et al., “Whole genome methylation array analysis reveals new aspects in Balkan endemic nephropathy etiology,” BMC Nephrology, vol. 14, article 225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Kocic, J. Cukuranovic, T. J. Stoimenov et al., “Global and specific histone acetylation pattern in patients with Balkan endemic nephropathy, a worldwide disease,” Renal Failure, vol. 36, no. 7, pp. 1078–1082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Lagos-Quintana, R. Rauhut, W. Lendeckel, and T. Tuschl, “Identification of novel genes coding for small expressed RNAs,” Science, vol. 294, no. 5543, pp. 853–858, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Alvarez-Garcia and E. A. Miska, “MicroRNA functions in animal development and human disease,” Development, vol. 132, no. 21, pp. 4653–4662, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. G. A. Calin, C. Sevignani, C. D. Dumitru et al., “Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999–3004, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Nikolova and D. Toncheva, “RNA interference-regulations and application in oncology,” Journal of Cancer Molecules, vol. 4, no. 3, pp. 67–77, 2008. View at Google Scholar · View at Scopus
  26. O. A. Kent and J. T. Mendell, “A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes,” Oncogene, vol. 25, no. 46, pp. 6188–6196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Gottardo, C. G. Liu, M. Ferracin et al., “Micro-RNA profiling in kidney and bladder cancers,” Urologic Oncology: Seminars and Original Investigations, vol. 25, no. 5, pp. 387–392, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Lu, G. Getz, E. A. Miska et al., “MicroRNA expression profiles classify human cancers,” Nature, vol. 435, no. 7043, pp. 834–838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Stenvang, A. N. Silahtaroglu, M. Lindow, J. Elmen, and S. Kauppinen, “The utility of LNA in microRNA-based cancer diagnostics and therapeutics,” Seminars in Cancer Biology, vol. 18, no. 2, pp. 89–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. miRBase: the microRNA database, http://microrna.sanger.ac.uk.
  31. L. Dyrskjøt, M. S. Ostenfeld, J. B. Bramsen et al., “Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro,” Cancer Research, vol. 69, no. 11, pp. 4851–4860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. A. Neely, K. M. Rieger-Christ, B. S. Neto et al., “A microRNA expression ratio defining the invasive phenotype in bladder tumors,” Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 1, pp. 39–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Wang, H. Zhang, H. He et al., “Up-regulation of microRNA in bladder tumor tissue is not common,” International Urology and Nephrology, vol. 42, no. 1, pp. 95–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. J. W. F. Catto, S. Miah, H. C. Owen et al., “Distinct microRNA alterations characterize high- and low-grade bladder cancer,” Cancer Research, vol. 69, no. 21, pp. 8472–8481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. H. van der Kwast and B. Bapat, “Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling,” Current Opinion in Urology, vol. 19, no. 5, pp. 516–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Schaefer, C. Stephan, J. Busch, G. M. Yousef, and K. Jung, “Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors,” Nature Reviews Urology, vol. 7, no. 5, pp. 286–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. M. F. Wszolek, K. M. Rieger-Christ, P. A. Kenney et al., “A MicroRNA expression profile defining the invasive bladder tumor phenotype,” Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 6, pp. 794–801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Lopez-Beltran, G. Sauter, T. Gasser et al., “Tumors of the urinary system. Infiltrating urothelial carcinoma,” in World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs, J. N. Eble, G. Sauter, J. I. Epstein, and I. A. Sesterhenn, Eds., pp. 93–109, IARC, Lyon, France, 2004. View at Google Scholar
  39. L. H. Sobin and C. Wittekind, Eds., TNM Classification of Malignant Tumors, Wiley-Liss, New York, NY, USA, 6th edition, 2002.
  40. C. Chen, D. A. Ridzon, A. J. Broomer et al., “Real-time quantification of microRNAs by stem-loop RT-PCR,” Nucleic Acids Research, vol. 33, no. 20, article e179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. miRNA Microarray System with miRNA Complete Labeling and Hyb Kit, http://www.agilent.com/cs/library/usermanuals/Public/G4170-90011_miRNA_Protocol_3.1.pdf.
  42. I. S. Vlachos, K. Zagganas, M. D. Paraskevopoulou et al., “DIANA-miRPath v3.0: deciphering microRNA function with experimental support,” Nucleic Acids Research, vol. 43, no. W1, pp. W460–W466, 2015. View at Publisher · View at Google Scholar
  43. M. V. Iorio, M. Ferracin, C.-G. Liu et al., “MicroRNA gene expression deregulation in human breast cancer,” Cancer Research, vol. 65, no. 16, pp. 7065–7070, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M. V. Iorio and C. M. Croce, “MicroRNAs in cancer: small molecules with a huge impact,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5848–5856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Wu, S. Zhu, and Y.-Y. Mo, “Suppression of cell growth and invasion by miR-205 in breast cancer,” Cell Research, vol. 19, no. 4, pp. 439–448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Gandellini, M. Folini, N. Longoni et al., “MiR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cε,” Cancer Research, vol. 69, no. 6, pp. 2287–2295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. Z. Hagman, B. S. Haflidadóttir, J. A. Ceder et al., “MiR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients,” British Journal of Cancer, vol. 108, no. 8, pp. 1668–1676, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Hamamoto, K. Soejima, S. Yoda et al., “Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma,” Molecular Medicine Reports, vol. 8, no. 2, pp. 456–462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. V. Orang, R. Safaralizadeh, and M. A. H. Feizi, “Insights into the diverse roles of miR-205 in human cancers,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 2, pp. 577–583, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Formosa, E. K. Markert, A. M. Lena et al., “MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells,” Oncogene, vol. 33, no. 44, pp. 5173–5182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. D. R. Lucon, C. D. S. Rocha, R. B. Craveiro et al., “Downregulation of 14q32 micrornas in primary human desmoplastic medulloblastoma,” Frontiers in Oncology, vol. 3, article 254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Zehavi, R. Avraham, A. Barzilai et al., “Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor,” Molecular Cancer, vol. 11, article 44, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Guan, Z. Yin, X. Li, W. Wu, and B. Zhou, “Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues,” Journal of Experimental & Clinical Cancer Research, vol. 31, article 54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Ma, P. Zhang, J. Yang, Z. Liu, Z. Yang, and H. Qin, “Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation,” International Journal of Cancer, vol. 130, no. 9, pp. 2077–2087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Gadducci, C. Sergiampietri, N. Lanfredini, and I. Guiggi, “Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research,” Gynecological Endocrinology, vol. 30, no. 4, pp. 266–271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Meng, Z. Li, J. Yan et al., “Tissue-specific microRNA responses in rats treated with mutagenic and carcinogenic doses of aristolochic acid,” Mutagenesis, vol. 29, no. 5, pp. 357–365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Tao, Y. Zeng, J. Wang et al., “Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo,” Molecular Medicine Reports, vol. 12, no. 5, pp. 6533–6546, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. Y.-Y. Wang, Z. Li, T. Chen, and X.-M. Zhao, “Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks,” IET Systems Biology, vol. 9, no. 4, pp. 141–146, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Wei, Y. Yao, P. K. Gupta, and Z. Bing, “miRNA expression in lower and upper urothelial carcinoma and the potential clinical application,” in Proceedings of the 102nd United States and Canadian Academy of Pathology Annual Meeting (USCAP '13), Baltimore Convention Center, Baltimore, Md, USA, March 2013.
  60. C. B. Madsen, C. Petersen, K. Lavrsen et al., “Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response,” PLoS ONE, vol. 7, no. 11, Article ID e50139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Radhakrishnan, S. Dabelsteen, F. B. Madsen et al., “Immature truncated O-glycophenotype of cancer directly induces oncogenic features,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 39, pp. E4066–E4075, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. M.-X. Ding, H.-F. Wang, J.-S. Wang et al., “PpGalNac T1 as a potential novel marker for human bladder cancer,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 11, pp. 5653–5657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. M.-C. Lin, M.-J. Huang, C.-H. Liu, T.-L. Yang, and M.-C. Huang, “GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity,” Oral Oncology, vol. 50, no. 5, pp. 478–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. Y.-M. Wu, C.-H. Liu, R.-H. Hu et al., “Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor,” Cancer Research, vol. 71, no. 23, pp. 7270–7279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Taniuchi, R. L. Cerny, A. Tanouchi et al., “Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth,” Oncogene, vol. 30, no. 49, pp. 4843–4854, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. Z.-Q. Wang, M. Bachvarova, C. Morin et al., “Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation,” Oncotarget, vol. 5, no. 2, pp. 544–560, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Li and Z. Zhang, “Potential microRNA-mediated oncogenic intercellular communication revealed by pan-cancer analysis,” Scientific Reports, vol. 4, article 7097, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. KEGG pathway: hsa04151, http://www.kegg.jp/dbget-bin/www_bget?hsa04151.